Alfonso Berrocal - Concepedia

Author

Alfonso Berrocal

Hospital General Universitario De Valencia ORCID

Also Known As

A Berrocal, A. BERROCAL, A. Berrocal, A. Martín Berrocal, Ainara Soria, Alfonso Berrocal, J. L. Manzano, Jose Luis Manzano, Maria Gonzalez-Cao, Milagros Isabel Rivas Mendoza

119

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Hospital General Universitario De Valencia Hospital Clínic de Barcelona Hospital Universitario La Paz Hospital General Universitario Gregorio Marañón Hospital Universitario Virgen Macarena

About

Alfonso Berrocal is an author at Hospital General Universitario De Valencia specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2.5K
2	Health Sciences	7	7	498
3	Immunology	2	2	58
4	Cell Biology	1	1	113
5	Diagnostic Sciences	1	1	15

Alfonso Berrocal

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer Ricardo Hitt, Juan J. Grau, Antonio López–Pousa, Annals of Oncology Neck CancerNeoadjuvant TherapyRadiation TherapyMedicineUnresectable Head	2013	345
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella, Journal of Clinical Oncology	2022	124
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR Miguel Vizoso, Humberto J. Ferreira, Paula López-Serra, Nature Medicine MedicineMelanomaEpigenetic ActivationSystems BiologyCancer Biology	2015	113
Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) Ricardo Hitt, Juan J. Grau, Antonio López–Pousa, Journal of Clinical Oncology Neck CancerNeoadjuvant TherapyCancer ManagementCrt Versus CrtOncology	2009	69
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial Carmen Balañá, R. de las Peñas, Juan Manuel Sepúlveda-Sánchez, Journal of Neuro-Oncology Neuro-oncologyGenom 009MedicineNeoadjuvant TreatmentNeurology	2016	55
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study Viktor Grünwald, Diana Chirovsky, Winson Y. Cheung, Oral Oncology	2020	50
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry Óscar Gallego, Míriam Cuatrecasas, Manuel Benavides, Journal of Neuro-Oncology	2013	41
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial María González‐Cao, Clara Mayo de las Casas, Juana Oramás, Nature Communications	2021	40
Ipilimumab for advanced melanoma Alfonso Berrocal, Ana Arance, José A. López-Martín, Melanoma Research ImmunologyImmunoeditingPharmacotherapyImmunotherapeuticsDermatology	2014	39

Page 1